Duke Pioneers Gentler Breast Cancer Drugs

Dr. Kimberly Blackwell, who heads the Duke Cancer Institute's Breast Cancer Program, and a patient discuss the positive results of a combination drug clinical trial that extended survival with much reduced side effects for people with advanced breast cancer.